Accrued expenses and other current liabilities consisted of (in thousands):


	March 31, 2026		December 31, 2025
Accrued contracted research and development costs	$	8,350	$	6,380
Accrued compensation		1,166		6,552
Accrued general and administrative costs		1,109		1,338
Royalty agreement derivative liability		374		362
Lease liability		44		7
Total accrued expenses and other current liabilities	$	11,043	$	14,639

As of March 31, 2026, Accrued contracted research and development costs are primarily comprised of costs associated with MOLBREEVI for the treatment of autoimmune PAP, including expenses resulting from obligations under agreements with CROs, CMOs, and other outside service providers that provide services in connection with the Company's research and development activities.

As of March 31, 2026, Accrued compensation includes amounts to be paid to employees for salary, bonuses, vacation and non-equity performance-based compensation. At the end of any period, the amounts accrued for such compensation may vary due to many factors including, but not limited to, timing of payments to employees and vacation usage.